secwatch.observer — SEC 8-K summary
======================================

Issuer:     Kiniksa Pharmaceuticals International, plc (KNSA)
CIK:        0001730430
Form:       8-K
Filed at:   2024-01-04T23:59:59+00:00
Accession:  0001104659-24-001149
Event type: other_material
Sentiment:  positive
Materiality: 0.80
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Kiniksa reports ARCALYST 2023 net revenue $233.1M; abiprubart Phase 2 meets primary endpoint
--------------------------------------------------------------------------------

- ARCALYST 2023 net product revenue $233.1M, up ~90% YoY; Q4 2023 revenue $71.2M.
- 2024 ARCALYST net product revenue guidance set at $360M-$380M.
- Abiprubart Phase 2 RA trial met primary endpoint at 5 mg/kg weekly dose (p=0.0487); 5 mg/kg biweekly missed.
- Cash, equivalents, and short-term investments $206.3M expected to fund operations into at least 2027.
- ~9% of target 14,000 multiple-recurrence pericarditis patients on ARCALYST; salesforce expanded to ~85 reps.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1730430/000110465924001149/0001104659-24-001149-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1730430/000110465924001149/tm241815d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-24-001149

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer